What causes IgA (Immunoglobulin A) nephropathy or Minimal Change Disease (MCD) kidney disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Causes of IgA Nephropathy and Minimal Change Disease

IgA nephropathy is caused by a "four-hit" pathogenic process involving production of galactose-deficient IgA1, formation of autoantibodies against this abnormal IgA1, immune complex formation, and mesangial deposition leading to kidney damage, while minimal change disease is primarily a podocytopathy with immune dysregulation as the underlying mechanism.

IgA Nephropathy Pathogenesis

IgA nephropathy (IgAN) has a well-established pathogenic mechanism involving four key steps:

  1. Production of galactose-deficient IgA1 (Gd-IgA1): The first hit in the disease process 1
  2. Formation of autoantibodies: These antibodies target the abnormal Gd-IgA1 1
  3. Immune complex formation: Gd-IgA1 and autoantibodies form immune complexes 1
  4. Mesangial deposition: These immune complexes deposit in the mesangium, triggering kidney damage 1

The definitive diagnosis requires kidney biopsy showing:

  • Mesangial dominant or co-dominant IgA deposits by immunofluorescence
  • Often accompanied by C3 deposition
  • Electron-dense deposits in the mesangium on electron microscopy 1

Clinical Characteristics of IgA Nephropathy

  • Most commonly presents as asymptomatic microscopic hematuria with varying degrees of proteinuria
  • Some patients may present with macroscopic hematuria
  • Approximately 30% progress to end-stage kidney disease within 20 years despite treatment 1

Minimal Change Disease Pathogenesis

Minimal change disease (MCD) has a different pathophysiological basis:

  • Primary podocyte injury: MCD is classified as a "podocytopathy" affecting the glomerular podocytes 2
  • Immune dysregulation: Evidence suggests immunologic dysregulation plays a central role 3
  • T-cell involvement: A T-cell-driven circulating factor that interferes with glomerular permselectivity to albumin has been proposed 4
  • Cytoskeletal disruption: Alterations in the podocyte cytoskeleton and foot processes are key features 2

The diagnostic hallmarks of MCD include:

  • Absence of visible alterations by light microscopy
  • Extensive foot process effacement on electron microscopy 3
  • Hypertrophic podocytes may be seen on light microscopy 5

Clinical Characteristics of MCD

  • Presents with nephrotic syndrome (proteinuria >3.5g/day, hypoalbuminemia, edema)
  • Typically responsive to glucocorticoid therapy
  • Usually does not lead to chronic renal damage if responsive to steroids 3

Overlap Between IgA Nephropathy and MCD

Interestingly, some patients present with features of both conditions:

  • Cases of IgA nephropathy with nephrotic syndrome and minimal histologic changes have been reported 6
  • These patients typically show:
    • IgA-dominant or codominant deposits with mesangial proliferation
    • Extensive foot process effacement (median 90%)
    • Clinical presentation and treatment response more typical of MCD 6
    • Good response to corticosteroids

This raises the question of whether some cases represent a dual glomerulopathy or a common pathophysiologic variant 5, 6.

Prognostic Factors

For IgA nephropathy, poor prognostic factors include:

  • Proteinuria >1 g/day
  • Hypertension
  • Reduced eGFR at diagnosis
  • Unfavorable histological features
  • Persistent hematuria 1

For MCD, relapsing disease requiring long-term immunosuppression is associated with significant morbidity due to medication side effects 3.

Common Pitfalls

  1. Misdiagnosis: Both conditions require kidney biopsy for definitive diagnosis, as clinical presentation alone can be misleading
  2. Overlooking overlap syndromes: Failing to recognize cases with features of both diseases may lead to suboptimal treatment
  3. Assuming all nephrotic syndrome in IgAN has poor prognosis: Cases with MCD-like features may have favorable outcomes with appropriate therapy 6
  4. Underestimating the importance of electron microscopy: Essential for identifying foot process effacement in MCD and mesangial deposits in IgAN

Understanding the distinct pathogenic mechanisms of these diseases is crucial for appropriate management and prognostication.

References

Guideline

IgA Nephropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Minimal Change Disease.

Clinical journal of the American Society of Nephrology : CJASN, 2017

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

IgA nephropathy with minimal change disease.

Clinical journal of the American Society of Nephrology : CJASN, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.